Thermo Fisher Scientific

Your educational resource for biopharma, pharma, environmental, food and agriculture, industrial, and clinical labs

  • Categories
    • Advancing Materials
    • Advancing Mining
    • AnalyteGuru
    • Analyzing Metals
    • Ask a Scientist
    • Behind the Bench
    • Biotech at Scale
    • Clinical Conversations
    • Examining Food
    • Identifying Threats
    • Illuminating Semiconductors
    • Life in Atomic Resolution
    • Life in the Lab
    • OEMpowered
    • The Connected Lab
  • About Us
  • Contact
Accelerating ScienceAnalyteGuru / Pharmaceutical / Speed up Drug Development Process With Fit-for-Purpose Metabolite Identification Solutions

Speed up Drug Development Process With Fit-for-Purpose Metabolite Identification Solutions

By Sven Hackbusch | Sebastien Morin, Thermo Fisher Scientific 03.14.2024

This is part one of a three-part series on Thermo Fisher Scientific’s analytical instrument solutions for metabolite identification in the small molecule drug development process.

Metabolite identification (MetID) is a crucial and integral part of traditional small molecule drug discovery and development. In this context, metabolism describes the breakdown and conversion of xenobiotics into molecules that can be excreted from the body, as shown in Figure 1. However, rapid metabolism reduces the duration and potential efficacy of pharmaceuticals, so in early drug discovery stages, metabolic profiling from in vitro studies is employed to identify metabolic soft spots to inform optimization of lead compounds to attain desired pharmacokinetics. Additionally, metabolic profiling plays a critical role in evaluating the safety of the molecule, as intermediates in the drug metabolism can have toxic effects. As a result, regulatory bodies have published detailed guidance on required testing. (See relevant  FDA guidance). 

As described in this application note from Kate Comstock, et al., the Thermo Scientific Orbitrap Exploris 240 mass spectrometer can provide straightforward and comprehensive metabolite profiling, allowing informed decision-making for lead optimization efforts. This is enabled by sensitive high-resolution accurate mass measurements, fast polarity switching and MS2 fragmentation capabilities of the Orbitrap Exploris 240 MS. This is complemented with the intelligent AcquireX data acquisition mode and advanced data processing in the Thermo Scientific Compound Discoverer software.

Figure 1. Overview of drug metabolism for a xenobiotic compound with Phase I and II denoting different transformation reactions to 1) oxidize or introduce reactive groups and 2) conjugate polar species to increase hydrophilicity.

The application note further describes the data processing workflow with the Compound Discoverer software that effectively mines the data to enable metabolite profiling and identification using predefined processing templates. The software relies on both a targeted approach to detect predicted metabolites generated based on intelligent dealkylation/diarylation prediction and common metabolic pathways, as well as an orthogonal approach to identify unexpected or unknown metabolites based on isotopic pattern matching and compound class scoring.

Related information

Read the complete application note here and discover Thermo Fisher Scientific’s metabolite identification solutions on our website.

Blog Part 2 of 3: Advanced LC-MS Tools and Software Solutions to Ease Your Metabolite Identification Challenges
Blog Part 3 of 3: Leveraging LC-MS for Accurate Metabolite Identification (MetID) in Drug Discovery & Development

You can also find out more about Thermo Fisher Scientific cutting edge analytical instruments and software solutions to streamline and speed up any drug development processes in our Learning Center.

On LinkedIn? Visit our LinkedIn page #pharmaceutical #biopharmaceutical #MetID #CMD


 

Sven Hackbusch | Sebastien Morin

Sven Hackbusch is a Senior Application Scientist at Thermo Fisher Scientific, responsible for the development of LC/MS applications related to the identification and structural elucidation of unknown compounds in collaboration with customers in the Pharma/Biopharma markets. | Sebastien Morin is a Business Development Manager for the Pharma and Biopharma market at Thermo Fisher Scientific, having spent several years in both industry, and sales and marketing. Sebastien has a particular interest in small molecules drug discovery, having worked several years as a medicinal chemist prior to joining Thermo Fisher.
Biopharmaceutical Characterization Complexities: A Dive into Multi-Attribute Method (MAM)
How to Optimize Your Natural Abundance Isotope Ratio Analysis – Watch the Video

Privacy StatementTerms & ConditionsLocationsSitemap

© 2025 Thermo Fisher Scientific. All Rights Reserved.

Talk to us